Course: Outcome Comparison of High-Risk Native American Patients Who Did or Did Not Receive Monoclonal Antibody Treatment for COVID-19
CME Credits: 1.00
Released: 2021-09-21
Treatments for COVID-19 remain urgent and necessary despite increasing vaccine distribution. Studies suggest that monoclonal antibody (mAb) therapies prevent progression in early disease., In late 2020, the US Food and Drug Administration (FDA) issued an emergency use authorization (EUA) for 2 mAb therapies, bamlanivimab and a combination of casirivimab and imdevimab, to treat COVID-19., However, previous mAb studies, with a total of 852 participants (577 in one study and 275 in the other) did not report a reduction in patient mortality, and only 5 participants across both trials (0.6%) were Native American. We present a retrospective quality improvement study on an early mAb treatment program for high-risk Native American patients at the Whiteriver Service Unit (WRSU), a rural acute care facility that serves as the primary hospital and public health department on the Fort Apache Indian Reservation in eastern Arizona.
Educational Objective
To identify the key insights or developments described in this article
View Full Course